![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Ipsen’s Partner Roche Says Taspoglutide Meets Endpoint in Phase III Trial
Ipsen’s Partner Roche Says Taspoglutide Meets Endpoint in Phase III Trial
April 29, 2010
Ipsen, a global biopharmaceutical group, Thursday announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients
with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence.
MarketWatch
MarketWatch
Upcoming Events
-
21Oct